Prezent Appoints Janet Dorling to Board to Advance AI in Biopharma
Prezent has appointed Janet Dorling to its Board of Directors, a move aimed at accelerating its AI initiatives in the biopharmaceutical industry, announced in a press release. Dorling, who has over 25 years of leadership experience, is currently a Senior Vice President at Gilead Sciences, a global biopharmaceutical company.
Dorling's expertise in the biotech and pharma sectors is expected to be instrumental as Prezent continues to develop its AI platform for business presentations. Her previous experience with Prezent's platform, including its AI agent Astrid, has shown significant improvements in communication efficiency and quality.
The appointment is part of Prezent's broader strategy to enhance organizational productivity by addressing communication challenges. The company recently raised $20 million in funding to expand its AI capabilities into new industries and geographies, further supporting its mission to streamline business communication.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 25 Baba Raises $40 Million for AI Medicare and Medicaid Care Oct 24 Google Expands AI Tuberculosis Screening Across Africa and Indonesia Oct 24 Lunit and Summit Test AI Pathology for Ivonescimab Research Oct 23 Pathos AI Raises $237 Million at $3 Billion Valuation Oct 23 BioVid launches synthetic physician research platformLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read moreYou may also like
Jarrard Expands AI Consulting Team
Growth Acceleration Partners appoints Dwayne Stoltz as Vice President of AI
Prologue Medicines names Stephen Harrison chief scientific officer
Podium Surpasses $150 Million in AI Agent ARR
OnBoard Launches AI Assist for Board Meeting Preparation
Daily AI Brief: the AI news that matters, in your inbox.